(Q24240582)

1

0 references

Jonathan Craig

3

Jonathan C Craig

0 references

Giovanni Strippoli

6

Giovanni FM Strippoli

0 references

Grahame Elder

4

Grahame Elder

0 references

David McGregor

2

Cochrane Database of Systematic Reviews

David O McGregor

0 references

publication date

7 October 2009

0 references

published in

0 references

cites work

Dose-response study of 22-oxacalcitriol in patients with secondary hyperparathyroidism.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

1,25 dihydroxycholecalciferol effects in chronic dialysis. A double-blind controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Comparative efficacy of oral and intravenous calcitriol treatment in haemodialysis patients: effects on serum biochemistry and cytokine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Treatment of secondary hyperparathyroidism with intermittent oral high doses of 1-alpha-OHD3 plus pharmacological dose of 24,25(OH)2D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Comparison of the efficacy of two injectable forms of vitamin D3 and oral one-alpha in treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Intermittent oral 1alpha-hydroxyvitamin D2 is effective and safe for the suppression of secondary hyperparathyroidism in haemodialysis patients. 1alphaD2 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Comparison of the effects of calcitriol and maxacalcitol on secondary hyperparathyroidism in patients on chronic haemodialysis: a randomized prospective multicentre trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Effect of oral calcitriol pulse therapy on the lipid, calcium, and glucose homeostasis of hemodialysis-patients: its safety in a combination with oral calcium carbonate

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Calcitriol in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Implications of intermittent calcitriol therapy on growth and secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Intermittent calcitriol therapy in secondary hyperparathyroidism: a comparison between oral and intraperitoneal administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Low calcium dialysate and high-dose oral calcitriol in the treatment of secondary hyperparathyroidism in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Inhibition of parathyroid hormone: a dose equivalency study of paricalcitol and doxercalciferol

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Mineral metabolism, mortality, and morbidity in maintenance hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Renal osteodystrophy in predialysis and hemodialysis patients: comparison of histologic patterns and diagnostic predictivity of intact PTH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Identifying relevant studies for systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Paricalcitol-treated patients experience improved hospitalization outcomes compared with calcitriol-treated patients in real-world clinical settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

In subtotally nephrectomized rats 22-oxacalcitriol suppresses parathyroid hormone with less risk of cardiovascular calcification or deterioration of residual renal function than 1,25(OH)2 vitamin D3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Proximal muscle weakness in uremia. Case reports and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Impact of kidney bone disease and its management on survival of patients on dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Phosphate binders for preventing and treating bone disease in chronic kidney disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Interventions for preventing bone disease in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Lower risk for cardiovascular mortality in oral 1alpha-hydroxy vitamin D3 users in a haemodialysis population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Efficacy of 19-Nor-1,25-(OH)2D2 in the prevention and treatment of hyperparathyroid bone disease in experimental uremia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Meta-analysis of biochemical and patient-level effects of calcimimetic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Survival of patients undergoing hemodialysis with paricalcitol or calcitriol therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Activated injectable vitamin D and hemodialysis survival: a historical cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Vitamin D analogues for the treatment and prevention of bone disease in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

Interventions for bone disease in children with chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Assessment of combined 24,25(OH)2D3 and 1 alpha (OH)D3 therapy for bone disease in dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Mortality risk among hemodialysis patients receiving different vitamin D analogs

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Increased risk of hip fracture among patients with end-stage renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Controlled trial of falecalcitriol versus alfacalcidol in suppression of parathyroid hormone in hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Suppression of parathyroid hormone secretion in hemodialysis patients by a novel vitamin D analogue: 19-nor-1,25-dihydroxyvitamin D2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Intermittent doxercalciferol (1alpha-hydroxyvitamin D(2)) therapy for secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Suppression of parathyroid hormone secretion in hemodialysis patients: comparison of paricalcitol with calcitriol.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Paricalcitol dosing according to body weight or severity of hyperparathyroidism: a double-blind, multicenter, randomized study.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Initial dosing of paricalcitol based on PTH levels in hemodialysis patients with secondary hyperparathyroidism

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Intravenous paricalcitol for treatment of secondary hyperparathyroidism in children on hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Safety and efficacy of pulse and daily calcitriol in patients on CAPD: a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Management of Bone Disease, Calcium, Phosphate and Parathyroid Hormone

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Predictors and consequences of altered mineral metabolism: the Dialysis Outcomes and Practice Patterns Study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Double-blind trial of oral 1,25-dihydroxy vitamin D3 versus placebo in asymptomatic hyperparathyroidism in patients receiving maintenance haemodialysis.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Comparative effect of oral pulse and intravenous calcitriol treatment in hemodialysis patients: the effect on serum IL-1 and IL-6 levels and bone mineral density

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Clinical effect of intravenous calcitriol administration on secondary hyperparathyroidism. A double-blind study among 4 doses

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

The effect of peroral calcitriol in small doses on mild secondary hyperparathyroidism in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Comparison of 1 alpha-OH-vitamin D3 and high doses of calcium carbonate for the control of hyperparathyroidism and hyperaluminemia in patients on maintenance dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Prevention of hyperparathyroidism in patients on maintenance dialysis by intravenous 1-alpha-hydroxyvitamin D3 in association with Mg(OH)2 as sole phosphate binder. A randomized comparative study with the association CaCO3 +/- Mg(OH)2

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Effect of 24,25-dihydroxycholecalciferol on intestinal absorption of calcium and phosphate and on parathyroid hormone secretion in chronic renal failure

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Vascular calcification in long-term haemodialysis patients in a single unit: a retrospective analysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

'Pulse oral' versus intravenous calcitriol therapy in chronic hemodialysis patients. A prospective and randomized study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Controlled Trial of the Effects of 1,25-Dihydroxycholecalciferol in Patients Treated with Regular Dialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

A randomized trial of intermittent versus continuous oral alfacalcidol treatment of hyperparathyroidism in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021

Meta-analysis: vitamin D compounds in chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD005633.PUB2

7 January 2021